Editorial: 3Rs—Strategies for reduction and refinement of animal studies
Frontiers in Pharmacology · 17.04.2023 · 14
DOI: 10.3389/fphar.2023.1200965 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.04.2023. Verfasst von Eleonore Fröhlich und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Medical Research, Medical University of Graz, Graz, Austria. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Editorial on the Research Topic 3Rs-Strategies for reduction and refinement of animal studiesEthical guidelines in animal experimentation were defined as early as 1831 by the British psychologist Marshall Hall (Gorzalczany and Rodriguez Basso, 2021).The first concept of the 3Rs, which stands for replacement, reduction and refinement of animal studies, was presented in 1957 at the Universities Federal of Animal Welfare (UFAW) Symposium.An important step in the implementation of the concept in the member states was achieved by the adoption of the European Directive 2010/63/EU on the protection of animals used for scientific purposes in September 2010.It is a legal obligation, to apply the 3Rs in all aspects of the care and use of animals (https://ec.europa.eu/environment/chemicals/lab_animals/ index_en.htm).Its content is similar to existing guidelines in numerous countries worldwide.The 3Rs comprise a spectrum of very different strategies, ultimately resulting in the full replacement of animals in research and toxicological evaluation with human volunteer studies, tissues and established cell lines, and mathematical and computer models (Camenzind and Eggel, 2022).Partial replacement is achieved by using animals that, based on current scientific thinking, are not considered capable of experiencing suffering (e.g., bacteria, fungi, drosophila, nematode worms and embryonic and fetal forms of vertebrates).Reduction aims to achieve the best statistically significant result with the least number of animals by choosing an appropriate testing method and a properly designed study protocol.It also includes methods to maximize knowledge gain per animal used (e.g., longitudinal imaging, multi-omics technology).Refinement aims to minimize the amount of harm and suffering inflicted on research animals.This includes reduction in stress situations (e.g., improved handling of laboratory animal, environmental enrichment, entertainment in the enclosure with balls, hay, etc.), improved anesthesia and analgesia, and the setting of clear criteria for curtailing testing.The contributions to this Research Topic focused on mathematical and computer models (physiologically based kinetic modeling (PBK), machine-learning algorithms and establishment of databases) to replace animal studies.Widjaja et al. studied the kinetics of glutathione-dependent adduct formation of the pyrrolizidine alkaloid (PA) senecionine to determine the mechanism of hepatotoxicity of PA-N-oxides when reduced to their parent PAs.The parent PAs are bioactivated to pyrrole intermediates which form protein and DNA adducts.The rate of glutathione-dependent adduct formation of senecionine was determined in rat liver microsomal fractions and used
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Medical Research, Medical University of Graz, Graz, Austria.
- Health and Safety Executive, Bootle, United Kingdom.
Zitieren
APA
Fröhlich, E., & Loizou, G. D. (2023). Editorial: 3Rs—Strategies for reduction and refinement of animal studies. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1200965
Vancouver
Fröhlich E, Loizou GD. Editorial: 3Rs—Strategies for reduction and refinement of animal studies. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1200965
BibTeX
@article{Frhlich2023,
author = {Fröhlich, Eleonore and Loizou, George D},
title = {Editorial: 3Rs—Strategies for reduction and refinement of animal studies},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1200965}
}
EUVIMED